Drug: obinutuzumab (Gazyva, Genentech)
Status: The therapy was approved for use in combination with bendamustine (Treanda, Teva) followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a regimen containing rituximab (Rituxan, Genentech).
Significant Trial Data:
- Three hundred twenty-one patients with FL were randomly assigned to receive either six cycles of obinutuzumab plus bendamustine followed